Analyst Ratings for Idenix Pharmaceuticals Inc. (IDIX) [Neutrals]
IDIX Rating Summary
IDIX Price Target Summary
- Highest: $14.00 (William Blair)
- Lowest: $5.00 (Maxim Group)
- Average: $8.44
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$8.44 (+102.5%)
Avg. $ Target:
$8.44 (+102.5%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/12/2013 | Baird | New Coverage | Neutral (N/A) |
5.00 (N/A) |
4.86 | 4.17 | -14.2% | Details |
| 1/30/2013 | Wedbush | Downgrade | Neutral (Outperform) |
6.00 (7.00) |
4.74 | 4.17 | -12.03% | Details |
| 11/12/2012 | Maxim Group | Downgrade | Hold (Buy) |
5.00 (11.00) |
4.17 | 4.17 | 0% | Details |
| 9/19/2012 | BofA/Merrill Lynch | Downgrade | Neutral (Buy) |
N/A (N/A) |
5.64 | 4.17 | -26.06% | Details |
| 8/17/2012 | Brean Capital | Upgrade | Hold (Sell) |
N/A (N/A) |
5.84 | 4.17 | -28.6% | Details |
| 8/16/2012 | Stifel Nicolaus | Upgrade | Hold (Sell) |
N/A (N/A) |
8.31 | 4.17 | -49.82% | Details |
| 4/30/2012 | JMP Securities | Upgrade | Market Perform (N/A) |
N/A (N/A) |
8.55 | 4.17 | -51.23% | Details |
| 4/17/2012 | Credit Suisse | New Coverage | Neutral (N/A) |
N/A (N/A) |
7.39 | 4.17 | -43.57% | Details |
| 2/10/2012 | Barclays » Updated 8/17/2012 |
New Coverage | Equalweight (N/A) |
7.00 (10.00) |
11.13 | 4.17 | -62.53% | Details |
| 3/18/2011 | Morgan Stanley | New Coverage | Equalweight (N/A) |
N/A (N/A) |
2.74 | 4.17 | 52.19% | Details |
| 2/10/2011 | Oppenheimer | Downgrade | Perform (N/A) |
N/A (N/A) |
2.99 | 4.17 | 39.46% | Details |
